Overview
Compare with INNO HOLDINGS INC., Rent The Runway or NaaS Technology Inc., or pick any stock.
- TickerRMTG on OTC1
- IndustryRetail-Retail Stores, NEC1
- HeadquartersBoca Raton, Florida1
- Business address433 Plaza Real Suite 275, Boca Raton, Fl 334322
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Cellular Institute and our affiliated network while promoting utilization of the Company’s proprietary Cellgenic product portfolio.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product Supplies brought in 40% of the revenue Regenerative Medical Technology Group Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product Supplies | $1.7M | $2.0M |
| Patient Procedures | $1.4M | $1.9M |
| Training | $809.7K | $1.1M |
| Equipments | $177.2K | $75.8K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue45¢$2.3M
- Other costs23¢$1.2M
- Income tax32¢$1.6M
Out of $5.1M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $5.1M | $4.1M |
| Cost of revenue | $2.3M | $1.3M |
| Gross profit | $2.8M | $2.8M |
| Advertising and marketing | $716.7K | $456.4K |
| Professional fees | $1.4M | $1.1M |
| Officer compensation | $90.0K | $90.0K |
| Depreciation and amortization expense | $281.1K | $220.6K |
| Investor relations | $80.0K | $52.2K |
| General and administrative | $1.1M | $798.3K |
| Total operating expenses | $3.7M | $2.7M |
| Net income (loss) from operations | -$867.2K | $81.2K |
| Interest expense | -$7.4M | -$5.6M |
| Change in fair value of derivative liability | $918.7K | -$2.5K |
| Loss on extinguishment of debt | -$416.2K | |
| Total other income (expense) | -$6.9M | -$5.6M |
| Net loss | -$7.8M | -$5.6M |
| Net loss per common share, basic (in Dollars per share) | -$0.62 | -$0.44 |
| Net loss per common share, diluted (in Dollars per share) | -$0.62 | -$0.44 |
| Weighted average number of common shares outstanding, basic (in Shares) | 12.6M shares | 12.5M shares |
| Weighted average number of common shares outstanding, Diluted (in Shares) | 12.6M shares | 12.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $956.7K | $1.2M | |
| Accounts receivable | $43.8K | $22.6K | |
| Inventory | $159.3K | $10.1K | |
| Prepaid expenses | $63.0K | $49.7K | |
| Total current assets | $1.2M | $1.2M | |
| Property and equipment, net | $870.8K | $451.7K | |
| Other assets | $32.5K | $7.3K | |
| Intangible assets, net | $61.5K | $159.0K | |
| Right of use asset, net | $621.2K | $275.3K | |
| Goodwill | $1.7M | $1.7M | $1.7M |
| Total assets | $4.5M | $3.8M | |
| Accounts payable and accrued liabilities | $348.4K | $563.7K | |
| Accrued interest | $16.6M | $10.5M | |
| Customer advances | $351.2K | $55.7K | |
| Derivative liability | $2.4M | $4.7K | |
| Lease liability | $220.0K | $63.5K | |
| Convertible notes payable, net | $47.5K | $43.1K | |
| Notes payable, net | $16.9M | $17.7M | |
| Total current liabilities | $36.8M | $29.0M | |
| Lease liability, net of current portion | $409.1K | $211.7K | |
| Notes payable, net of current portion | $2.0M | $2.0M | |
| Total liabilities | $39.2M | $31.2M | |
| Common stock, $0.001 par value: 100,000,000 shares authorized: 13,138,968 and 12,538,968 issued and outstanding for the years ended December 31, 2025, and December 31, 2024, respectively | $13.1K | $12.5K | |
| Additional paid in capital | $40.6M | $40.2M | |
| Accumulated deficit | -$75.4M | -$67.6M | |
| Total stockholders deficit | -$34.7M | -$27.4M | -$21.8M |
| Total liabilities and stockholders deficit | $4.5M | $3.8M | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares issued (in Shares) | 13.1M shares | 12.5M shares | |
| Common stock, shares outstanding (in Shares) | 13.1M shares | 12.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $956.7K | $1.2M | |
| Accounts receivable | $43.8K | $22.6K | |
| Inventory | $159.3K | $10.1K | |
| Prepaid expenses | $63.0K | $49.7K | |
| Total current assets | $1.2M | $1.2M | |
| Property and equipment, net | $870.8K | $451.7K | |
| Other assets | $32.5K | $7.3K | |
| Intangible assets, net | $61.5K | $159.0K | |
| Right of use asset, net | $621.2K | $275.3K | |
| Goodwill | $1.7M | $1.7M | $1.7M |
| Total assets | $4.5M | $3.8M | |
| Accounts payable and accrued liabilities | $348.4K | $563.7K | |
| Accrued interest | $16.6M | $10.5M | |
| Customer advances | $351.2K | $55.7K | |
| Derivative liability | $2.4M | $4.7K | |
| Lease liability | $220.0K | $63.5K | |
| Convertible notes payable, net | $47.5K | $43.1K | |
| Notes payable, net | $16.9M | $17.7M | |
| Total current liabilities | $36.8M | $29.0M | |
| Lease liability, net of current portion | $409.1K | $211.7K | |
| Notes payable, net of current portion | $2.0M | $2.0M | |
| Total liabilities | $39.2M | $31.2M | |
| Common stock, $0.001 par value: 100,000,000 shares authorized: 13,138,968 and 12,538,968 issued and outstanding for the years ended December 31, 2025, and December 31, 2024, respectively | $13.1K | $12.5K | |
| Additional paid in capital | $40.6M | $40.2M | |
| Accumulated deficit | -$75.4M | -$67.6M | |
| Total stockholders deficit | -$34.7M | -$27.4M | -$21.8M |
| Total liabilities and stockholders deficit | $4.5M | $3.8M | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares issued (in Shares) | 13.1M shares | 12.5M shares | |
| Common stock, shares outstanding (in Shares) | 13.1M shares | 12.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$7.8M | -$5.6M |
| Amortization of debt discount | $1.4M | $2.1M |
| Depreciation and amortization expense | $281.1K | $220.6K |
| Changes in fair value of derivative liability | -$918.7K | $2.5K |
| Common shares issued for conversion of note | $22.8K | |
| Loss on extinguishment of debt | $416.2K | |
| Preferred shares issued with debt | $401 | |
| Accounts receivable | -$21.2K | $1.4K |
| Prepaid expenses | -$13.3K | -$29.2K |
| Inventory | -$149.2K | -$10.1K |
| Other assets | -$25.3K | -$1.7K |
| Accounts payable and accrued liabilities | $6.1M | $4.1M |
| CASH PROVIDED (USED) BY OPERATING ACTIVITIES | -$706.5K | $850.7K |
| Purchase of property and equipment | -$602.6K | -$215.4K |
| CASH USED BY INVESTING ACTIVITIES | -$602.6K | -$215.4K |
| Proceeds from issuance of debt | $1.1M | |
| CASH PROVIDED BY FINANCING ACTIVITIES | $1.1M | |
| Net increase (decrease) in cash | -$209.1K | $635.3K |
| Warrants discount issued on debt | $3.3M | |
| Common stock issued for conversion of note | $22.8K | $1.8K |
No quarter-by-quarter statement was filed.
Compare Regenerative Medical Technology Group Inc. with another company
What it owns
What Regenerative Medical Technology Group Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $615.2K4 Dec 31, 2025 | $431.7K4 Dec 31, 2024 | +42.5% |
| Property and equipment, net | $870.8K4 Dec 31, 2025 | $451.7K4 Dec 31, 2024 | +92.8% |
| Operating-lease assets (leased space) | $621.2K4 Dec 31, 2025 | $275.3K4 Dec 31, 2024 | +125.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $956.7K4 Dec 31, 2025 | $1.2M4 Dec 31, 2024 | −17.9% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $1.7M4 Dec 31, 2025 | $1.7M4 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $61.5K4 Dec 31, 2025 | $159.0K4 Dec 31, 2024 | −61.3% |
| Accumulated amortization | $426.2K4 Dec 31, 2025 | $328.7K4 Dec 31, 2024 | +29.7% |
Inventory
Properties, in its own words
We maintain our current principal office at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432. Our phone number is (800) 956-3935. This location serves as our administrative headquarters in the United States.
Our primary operational facilities are located in Cancún, Quintana Roo, Mexico, where we conduct patient treatments, physician training, and manufacturing of regenerative medicine products through our subsidiary, Global Stem Cells Group, Inc. (GSCG), and its division Cellgenic.
The rest of Item 2
The Cancún operations are situated in the Tulum Trade Center, a modern commercial complex located at Boulevard Luis Donaldo Colosio, Manzana 1, Lote 3, Supermanzana 9, Cancún, Quintana Roo, Mexico. This facility serves as both our clinical center for regenerative therapies and our advanced manufacturing site for mesenchymal stem cells (MSCs), exosomes, peptide-based products, and related biologics.
Lease History and Current Arrangements:
◾ · Initial Lease: Global Stem Cell Group, Inc. entered into a lease agreement with HELLIMEX, S.A. DE CV beginning January 16, 2022, and originally ending on January 15, 2024. The leased space consisted of approximately 1,647 square feet, with a monthly rent of $2,714 and a security deposit of $5,588. In January 2022, we initiated the buildout of the clinic and procurement of equipment. The Cancún facility is accredited by both the Mexican General Health Council and COFEPRIS (Mexico’s federal health regulatory authority equivalent to the FDA), enabling compliant operations for stem cell therapies and manufacturing.
◾ · Expansion Lease: Due to business growth and the need for additional space, we entered into a new lease with RIVIERA MAYA, S.A. DE C.V. beginning January 16, 2024, and originally ending on January 15, 2026. This added approximately 1,216 square feet to support expanded clinical and manufacturing activities.
◾ · Lease Extension: On December 31, 2025, the Company signed a five-year extension to the combined lease arrangements, effective from December 31, 2025, through December 31, 2029. The monthly rent and security deposit terms remained unchanged at $2,714 per month and $5,588, respectively. This extension provides long-term stability for our core operations.
Additional Leases in 2025:
◾ · On July 31, 2025, the Company signed a three-year lease for additional space consisting of 1,290 square feet located at Av. Bonampak #SM4A M1 Lote 4C, Int. Local 401, Col. SM 4A, Localidad Benito Juárez, Cancún, Quintana Roo C.P. 77500, MX. The lease commences on July 31, 2025, and ends on June 30, 2028, with a monthly rent of $10,000 for the first year and a 3.56% annual increase beginning in the second year. A security deposit of $20,000 was paid.
◾ · On October 30, 2025, the Company signed a five-year lease for additional office space consisting of 1,205 square feet at the Tulum Trade Center. The lease commences on November 1, 2025, and ends on October 31, 2030, with a monthly rent of $3,500 for the first year and a 4% annual increase beginning in the second year. A security deposit of $5,300 was paid.
The Cancún facility is fully licensed by COFEPRIS to function as a Stem Cell Collection Center, Stem Cell Bank, and advanced manufacturing center. It supports our vertical integration strategy, enabling in-house production of high-quality regenerative products for our global clinic network and distribution. The facility’s strategic location in Cancún facilitates access to international patients and aligns with our focus on medical tourism and regenerative treatments in Mexico.
We do not own any real property and lease all our facilities on market terms. We believe our current leased properties are adequate for our present and near-term needs, with flexibility to expand as our operations grow in key international markets. We continue to evaluate additional locations for future clinic expansions and potential manufacturing sites, subject to regulatory and market conditions.
Item 2 of the 10-K filed May 14, 2026.3
Leadership
Who has led Regenerative Medical Technology Group Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
- Chief executive officerDavid Eugene Christensen Apr 21, 2021 to Aug 19, 202112
- Chief executive officerMelvin Antonio Loria Pereira Dec 12, 2018 to Dec 12, 201813
- ChairMelvin Antonio Loria Pereira Dec 12, 2018 to Dec 12, 201813
- PresidentDavid Eugene Christensen Apr 21, 2021 to Apr 21, 202112
Board members and other officers (1)
- Board memberDavid Eugene Christensen Apr 21, 2021 to Apr 21, 202112
Former names
- MESO NUMISMATICS, INC.Dec 12, 2018 to Oct 24, 20242
Timeline
- Aug 25, 20268-K Other events14
- May 21, 20258-K Results of operations15
- Nov 19, 20248-K Results of operations16
- Oct 24, 20248-K Other events17
- May 23, 20248-K Results of operations18
- Dec 13, 20238-K Entered a material agreement; Unregistered sale of shares19
- Sep 27, 20238-K Change of auditor20
- Mar 23, 20228-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares21
- Dec 2, 20218-K Change of auditor22
- Apr 21, 2021New chief executive David Eugene Christensen becomes CEO12
- Dec 12, 2018New chief executive Melvin Antonio Loria Pereira becomes CEO13
Calendar
When it reported results
- May 21, 2025Reported quarterly or annual results15
- Nov 19, 2024Reported quarterly or annual results16
- May 23, 2024Reported quarterly or annual results18
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
59 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 9 major events, 30 other. The latest 20:
- Aug 28, 2026DEF 14C DEFINITIVE INFORMATION STATEMENT EDGAR
- Aug 25, 20268-K CURRENT REPORT EDGAR
- Aug 19, 202610-Q QUARTERLY REPORT EDGAR
- Aug 18, 2026PRE 14C PRELIMINARY INFORMATION STATEMENT EDGAR
- Aug 14, 2026NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- Jun 9, 202610-Q QUARTERLY REPORT EDGAR
- May 15, 2026NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- May 14, 202610-K ANNUAL REPORT EDGAR
- Apr 1, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
- Nov 19, 202510-Q QUARTERLY REPORT EDGAR
- Nov 14, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- Aug 19, 202510-Q QUARTERLY REPORT EDGAR
- Aug 13, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- Jun 27, 2025EFFECT EDGAR
- Jun 25, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 EDGAR
- Jun 12, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 EDGAR
- May 21, 20258-K CURRENT REPORT EDGAR
- May 20, 202510-Q QUARTERLY REPORT EDGAR
- May 14, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- Apr 15, 202510-K ANNUAL REPORT EDGAR
The 59 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How Regenerative Medical Technology Group Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARRegenerative Medical Technology Group Inc.1
- CIK0001760026
- Employer ID (EIN)88-04921913
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inNevada3
- Fiscal year endsDecember 311
- Industry code (SIC)5990 Retail-Retail Stores, NEC1
- SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
- Business address433 Plaza Real Suite 275, Boca Raton, FL 334321
- Phone800-889-95091
- Shares outstanding13,738,968 as of Aug 19, 202611
- Public float$612.5K as of Jun 30, 20253
- AuditorVictor Mokuolu CPA PLLC, Houston, Texas PCAOB ID 6771; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceDec 12, 20181
- Filings101 in all: 10-Q (23), 8-K (20), NT 10-Q (13), 10-K (8), NT 10-K (8), UPLOAD (5), 3 (3), CORRESP (3)1
All 19 form types
EFFECT (3), POS AM (3), 10-12G/A (2), DEF 14C (2), PRE 14C (2), 10-12G (1), 4 (1), 8-K/A (1), PRER14C (1), S-1 (1), SC 13G (1)
- Latest filingsAnnual report (10-K) May 14, 2026
Quarterly report (10-Q) Aug 19, 2026
Latest 8-K (8-K) Aug 25, 2026
Risk factors and legal proceedings
The risks Regenerative Medical Technology Group Inc. names in Item 1A of its 10-K filed May 14, 2026: 11 risks under these headings, as written.3
- Risks Related to Macroeconomics, Public Health Emergencies and Other Conditions
- RISKS AND UNCERTAINTIES ASSOCIATED WITH OUR OPERATIONS OUTSIDE OF THE UNITED STATES MAY ADVERSELY AFFECT OUR RESULTS OF OPERATIONS, CASH FLOW, LIQUIDITY OR FINANCIAL CONDITION
- Risks Related to Our Financial Condition
- We have a limited operating history.
- Our ability to generate the significant amount of cash needed to service our debt obligations and our ability to refinance all or a portion of our indebtedness or obtain additional financing depends on many factors, many of which may be beyond our control.
- Risks Related to Our Business
- The Operations and Commercialization of Stem Cell Therapies is an exciting, new, and integral part of the emerging Regenerative Medicine market, BUT The field remains in its infancy.
- Some of Our Potential Cell Therapy Products and Technologies Are In Early Stages Of Development.
- We intend to continue strategic business acquisitions and other combinations, which are subject to inherent risks.
- If we are unable to manage our growth in the new markets in which we offer solutions or services, our business and financial results could suffer.
- Risks Related to Legal Uncertainty
- We may become subject to legal proceedings that could have a material adverse impact on our financial position and results of operations.
The other 3 risks
- If we should in the future become required to obtain regulatory approval to market and sell our pRODUCTS AND services we will not be able to generate any revenues until such approval is received.
- We may be unable to protect our intellectual property from infringement by third parties, and third parties may claim that we are infringing on their intellectual property, either of which could materially and adversely affect us.
- We may be Exposed to Liabilities under the Foreign Corrupt Practices Act and any Determination that we Violated these Laws could have a Material Adverse Effect on our Business.
- Risks Related to Our Management and Control Persons
- Risks Related to Our Common Stock
Legal proceedings
To the Company’s knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our Company’s subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGAROther events
- 15SEC EDGARResults of operations
- 16SEC EDGARResults of operations
- 17SEC EDGAROther events
- 18SEC EDGARResults of operations
- 19
- 20SEC EDGARChange of auditor
- 21
- 22SEC EDGARChange of auditor